Compare · BRKR vs NAUT
BRKR vs NAUT
Side-by-side comparison of Bruker Corporation (BRKR) and Nautilus Biotechnology Inc. (NAUT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BRKR and NAUT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BRKR is the larger of the two at $8.66B, about 77.2x NAUT ($112.2M).
- Over the past year, BRKR is up 67.0% and NAUT is up 23.8% - BRKR leads by 43.2 points.
- BRKR has been more active in the news (19 items in the past 4 weeks vs 1 for NAUT).
- BRKR has more recent analyst coverage (22 ratings vs 7 for NAUT).
- Company
- Bruker Corporation
- Nautilus Biotechnology Inc.
- Price
- $56.86-0.22%
- $0.88+0.91%
- Market cap
- $8.66B
- $112.2M
- 1M return
- -5.30%
- -47.05%
- 1Y return
- +67.04%
- +23.82%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 19
- 1
- Recent ratings
- 22
- 7
Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Nautilus Biotechnology Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the human proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company is headquartered in Seattle, Washington.
Latest BRKR
- Chief Accounting Officer Bures Thomas was granted 4,035 shares, increasing direct ownership by 126% to 7,233 units (SEC Form 4)
- President BMID Group Pusch Wolfgang sold $197,614 worth of shares (3,473 units at $56.90) and was granted 3,120 shares, decreasing direct ownership by 3% to 9,801 units (SEC Form 4)
- EXECUTIVE VICE PRESIDENT, CFO Herman Gerald N was granted 15,794 shares and covered exercise/tax liability with 2,724 shares, increasing direct ownership by 13% to 111,354 units (SEC Form 4) to cover taxes
- EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19, sold $115,200 worth of shares (2,000 units at $57.60) as part of a pre-agreed trading plan, was granted 14,443 shares and covered exercise/tax liability with 2,984 shares, increasing direct ownership by 9% to 134,806 units (SEC Form 4) (for tax liability)
- PRESIDENT & CEO Laukien Frank H was granted 29,463 shares and covered exercise/tax liability with 4,760 shares, increasing direct ownership by 0.06% to 38,507,043 units (SEC Form 4) to cover withholding tax
- PRESIDENT CALID Srega Juergen was granted 16,898 shares, increasing direct ownership by 11% to 174,625 units (SEC Form 4)
- PRES. & CEO, BRUKER BEST Prause Burkhard was granted 3,303 shares, increasing direct ownership by 13% to 28,461 units (SEC Form 4)
- EXEC VP&PRES BRUKER NANO INC. Munch Mark covered exercise/tax liability with 1,619 shares, decreasing direct ownership by 1% to 123,347 units (SEC Form 4) to satisfy withholding obligation
- PRESIDENT & CEO Laukien Frank H covered exercise/tax liability with 4,838 shares, decreasing direct ownership by 0.01% to 38,482,340 units (SEC Form 4) (tax withholding)
- EXECUTIVE VICE PRESIDENT, CFO Herman Gerald N covered exercise/tax liability with 1,410 shares, decreasing direct ownership by 1% to 98,284 units (SEC Form 4) (for tax liability)
Latest NAUT
- Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.
- SEC Form 10-Q filed by Nautilus Biotechnology Inc.
- Nautilus Biotechnology Reports Second Quarter 2026 Financial Results
- Nautilus Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
- Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.
- SEC Form 4 filed by Director Posard Matthew L.
- SEC Form 4 filed by Director Akinsanya Karen
- SEC Form 4 filed by Director Nazem Farzad
- SEC Form 4 filed by Director Mcilwain Matthew S